Quality Evaluation System for Colonoscopy Clinical Trial
Official title:
Prospective Multicenter Study of Artificial Intelligence-assisted Quality Evaluation System for Colonoscopy
| NCT number | NCT04610177 |
| Other study ID # | EA-20-003 |
| Secondary ID | |
| Status | Recruiting |
| Phase | |
| First received | |
| Last updated | |
| Start date | June 2, 2020 |
| Est. completion date | December 16, 2021 |
The quality control index based on artificial intelligence is put forward to monitor the quality of enteroscopy. And we will verify the correlation between the detection rate of adenomas and the percentage of endoscopic overspeed mirrors, the number of times of no-return/successful return, the real-time Bowel preparation provided by EndoAngel. What's more, it is expected that the standard range of quality control index for standard operation of colonoscopy can be proposed according to the detection rate of adenomas.
| Status | Recruiting |
| Enrollment | 5813 |
| Est. completion date | December 16, 2021 |
| Est. primary completion date | December 2, 2021 |
| Accepts healthy volunteers | No |
| Gender | All |
| Age group | 50 Years to 80 Years |
| Eligibility | Inclusion Criteria: 1. Male or female aged 50-80(inclusive) ; 2. Ability to read, understand and sign an informed consent form; 3. The researchers believed that the subjects were able to understand the flow of the clinical study and were willing and able to complete all the procedures and follow-up interviews to accompany the study. Exclusion Criteria: Participants who meet any of the following criteria will be excluded from the study 1. Drug or alcohol abuse or psychological disorders in the last 5 years; 2. Pregnant or lactating women; 3. Patients with known Polyp Syndrome; 4. Patients with known Inflammatory Bowel Disease; 5. Patients with known Intestinal stricture or mass tumor; 6. Patients with known colonic obstruction or perforation; 7. Patients with a previous history of colorectal surgery; 8. Patients with a previous history of Anaphylaxis to antispasmodic agents; 9. Blood coagulation disorders or oral anticoagulants and other reasons can not be biopsy and polypectomy; 10. High-risk diseases or other special conditions considered unsuitable for participants in clinical trials. |
| Country | Name | City | State |
|---|---|---|---|
| China | Renmin Hospital of Wuhan University | Wuhan | Hubei |
| Lead Sponsor | Collaborator |
|---|---|
| Renmin Hospital of Wuhan University |
China,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Percentage of enteroscopy exit velocity overdrive | Percentage of enteroscopy exit velocity overdrive | 2020.12.2 | |
| Primary | The adenoma detection rate(ADR) | ADR was calcilated by dividing the tatal number of patients being detected adenomas by the number of colinoscopies. | 2020.12.2 | |
| Secondary | The advanced adenoma detection rate | The advanced adenoma detection rate was calcilated by dividing the tatal number of patients being detected advanced adenomas by the number of colinoscopies. | 2020.12.2 | |
| Secondary | The polyp detection rate(PDR) | PDR was calcilated by dividing the tatal number of patients being detected polyps by the number of colinoscopies. | 2020.12.2 | |
| Secondary | The mean number of adenomas per patient(MAP) | MAP was calculated by dividing the total number of adenomas by the number of colonoscopies. | 2020.12.2 | |
| Secondary | PDR of different size | It was calculated by dividing the number of patients with polyps that large (=10mm), small(6-9 mm) and diminutive(=5 mm) by the number of patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | MNP of different size | It was calculated by dividing the number of polyps that large (=10mm), small(6-9 mm) and diminutive(=5 mm) by the number of patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | ADR of different size | It was calculated by dividing the number of patients with adenomas that large (=10mm), small(6-9 mm) and diminutive(=5 mm) by the number of patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | MAP of different size | It was calculated by dividing the number of adenomas that large (=10mm), small(6-9 mm) and diminutive(=5 mm) by the number of patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | ADR of different location | It was calculated by dividing the number of patients with adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | MAP of different location | It was calculated by dividing the number of adenomas detected in the rectum, sigmoid colon, descending colon, transverse colon, ascending colon, ileocecal region ect. by the total number patients undergoing colonoscopy. | 2020.12.2 | |
| Secondary | Cecal intubation rate | It was calculated by dividing the number of colonoscopies that get to the ileocecal region by the total number of colonoscopies. | 2020.12.2 | |
| Secondary | Cleanliness assessment of different intestinal segment in the artificial intelligence system | The artificial intelligence evaluates the Boston Bowel Preparation score of the ascending colon, transverse colon,and descending colon in real-time, and calculates the proportion of 1Score. | 2020.12.2 |